

# A Sigma-1 Receptor Selective Analogue of BD1008. A Potential Substitute for (+)-Opioids in Sigma Receptor Binding Assays

Dean Y. Maeda,<sup>a</sup> Wanda Williams,<sup>b</sup> Wayne D. Bowen<sup>b</sup> and Andrew Coop<sup>a,\*</sup>

<sup>a</sup>Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, 20 North Pine Street, Baltimore, MD 21201, USA


<sup>b</sup>Laboratory of Medicinal Chemistry, National Institute of Digestive, Diabetes and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA

Received 3 September 1999; accepted 4 October 1999

**Abstract**—A simple, achiral monoamine sigma-1 ( $\sigma_1$ ) receptor selective ligand ( $\sigma_2 K_i/\sigma_1 K_i > 2000$ ) is described, which could replace the chiral (+)-pentazocine or dextralorphan as a  $\sigma_1$  masking agent in  $\sigma_2$  binding assays. © 1999 Elsevier Science Ltd. All rights reserved.

The sigma ( $\sigma$ ) receptor was first described by Martin as a subtype of opioid receptors, based on the actions of racemic benzomorphans such as ( $\pm$ )SKF10,047.<sup>1</sup> However, the fact that ( $\pm$ )SKF10,047 is a nonspecific ligand led to confusing pharmacological interpretations, where the effects due to interaction with opioid and phencyclidine sites were viewed as  $\sigma$  mediated effects.<sup>2</sup> It is now accepted that the  $\sigma$  receptor system consists of at least two subtypes, namely  $\sigma_1$  and  $\sigma_2$ , with pharmacological profiles distinct from any known receptor class.<sup>3</sup> The  $\sigma_1$  receptor was recently cloned, and represents a novel protein.<sup>4</sup> The  $\sigma_2$  receptor has yet to be cloned, and work is limited due to the paucity of selective ligands and the lack of a radiolabeled selective ligand for binding assays.<sup>3</sup> At present,  $\sigma_1$  binding affinity is assessed by displacement of the  $\sigma_1$  selective [<sup>3</sup>H]-(+)-pentazocine,<sup>3</sup> and  $\sigma_2$  affinity is assessed through the displacement of non-selective [<sup>3</sup>H]-ditolylguanidine ([<sup>3</sup>H]-DTG) in the presence of cold (+)-pentazocine or dextralorphan to mask  $\sigma_1$  sites.<sup>3,5</sup> Obviously, the use of a chiral material simply to block  $\sigma_1$  sites is not ideal. Although the development of a  $\sigma_2$  selective radiolabel is a major goal in this area, the current  $\sigma_2$  procedure could be improved by the development of an inexpensive achiral ligand with high  $\sigma_2/\sigma_1$  selectivity to block  $\sigma_1$  sites. Herein, we report the initial preparation and evaluation of a novel monoamine (AC915) with the above characteristics and a  $\sigma_2/\sigma_1$  selectivity of >2000-fold.

BD1008 (**1**) is a high affinity  $\sigma_1$  and  $\sigma_2$  ligand with great selectivity over other receptor systems (Table 1).<sup>6</sup> The fact that similar phenylpentylamines prepared by Glennon<sup>7</sup> displayed excellent  $\sigma_1$  affinity, led to the conclusion that the central basic nitrogen is not essential for  $\sigma_1$  affinity.<sup>8</sup> However, masking the central basic nitrogen as an amide, led to ligands of reduced  $\sigma_1$  and  $\sigma_2$  affinity,<sup>9</sup> showing that an amide is detrimental to  $\sigma_1$  affinity in this series. Thus, considering that a simple and economical synthesis was required, it was decided to investigate the removal of the nitrogen completely and introduce an ester.



## Chemistry and Pharmacology

1-(2-Hydroxyethyl)pyrrolidine was coupled with 3,4-dichlorophenylacetic acid by the use of DCC and DMAP in  $\text{CHCl}_3$  at ambient temperature overnight to give **2**, which was isolated by HCl extraction (1 M) and oxalic acid salt formation from acetone (mp 164–165 °C).<sup>10</sup>

\*Corresponding author. Tel.: +1-410-706-2029; fax: +1-410-706-0346.

**Table 1.** Binding affinities of **1**, **2** and (+)-pentazocine at sigma receptors

Compound	$K_i$ (nM) $\pm$ SEM		
	$\sigma_1^a$	$\sigma_2^b$	$\sigma_2/\sigma_1$
<b>2</b> (AC915)	4.89 $\pm$ 0.29	> 10,000	2040
<b>1</b> BD1008	2.2 $\pm$ 0.65	8.10 $\pm$ 2.2	4
(+)-Pentazocine	3.1 $\pm$ 0.3	1542 $\pm$ 313	500

<sup>a</sup>Displacement of <sup>3</sup>[H]-(+)-pentazocine.<sup>b</sup>Displacement of <sup>3</sup>[H]-DTG in the presence of dextrallorphan.

**2** was evaluated in competition assays at  $\sigma_1$  and  $\sigma_2$  sites (Table 1) using methods reported previously.<sup>3,5</sup>

These data show that **2** has only a 2-fold lower  $\sigma_1$  affinity than BD1008, but the introduction of the ester has abolished  $\sigma_2$  affinity, to give a compound of >2000-fold selectivity for  $\sigma_1$  receptors. Thus, it appears that the central nitrogen of **1** is not essential for recognition at  $\sigma_1$ , a finding in agreement with Glennon,<sup>7</sup> but is essential for recognition at  $\sigma_2$ .

The removal of the central amine of BD1008, and replacement with an ester has yielded a highly-selective achiral  $\sigma_1$  ligand, which can be easily and economically prepared without the need for chromatography. Thus, **2**

(AC915) has the required properties to replace the expensive (+)-opioids as a masking agent in  $\sigma_2$  binding assays.

## References and Notes

1. Martin, W. R.; Eades, C. E.; Thompson, J. A.; Huppler, R. E. *J. Pharmacol. Exp. Ther.* **1976**, *197*, 517.
2. Walker, J. M.; Bowen, W. D.; Walker, F. O.; Matsumoto, R. R.; de Costa, B. R.; Rice, K. C. *Pharmacol. Rev.* **1990**, *42*, 355.
3. Quirion, R.; Bowen, W. D.; Itzhak, Y.; Junien, J. L.; Musacchio, J. M.; Rothman, R. B.; Su, T. P.; Tam, S. W.; Taylor, D. P. A. *Trends Pharmacol. Sci.* **1992**, *13*, 85.
4. Hanner, M.; Moebius, F. F.; Flandorfer, A.; Knaus, H. G.; Striessnig, J.; Kempner, E.; Glossman, H. *Proc. Natl. Acad. Sci. USA* **1996**, *93*, 8072.
5. Hellewel, S. B.; Bruce, A.; Feinstein, G.; Orringer, J.; Williams, W.; Bowen, W. D. *Eur. J. Pharmacol.* **1994**, *268*, 9.
6. de Costa, B. R.; Radesca, L.; Paolo, L. D.; Bowen, W. D. *J. Med. Chem.* **1992**, *35*, 38.
7. El-Ashmawy, M.; Ablordeppey, S. Y.; Issa, H.; Gad, L.; Fisher, J. B.; Burke Howie, K. J.; Glennon, R. A. *Med. Chem. Res.* **1992**, *2*, 119.
8. The procedure used in ref 7 is known to predominantly measure  $\sigma_1$  affinity. See ref 3.
9. Zhang, Y.; Williams, W.; Torrence-Campbell, C.; Bowen, W. D.; Rice, K. C. *J. Med. Chem.* **1998**, *41*, 4950.
10. Spectra were consistent with structure **2**; the salt gave a satisfactory microanalysis ( $\pm 0.4\%$ ).